Inscrição na biblioteca: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Publicou 6 edições por ano

ISSN Imprimir: 1045-4403

ISSN On-line: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

The Importance of Mutational Drivers in GBM

Volume 26, Edição 1, 2016, pp. 19-26
DOI: 10.1615/CritRevEukaryotGeneExpr.v26.i1.30
Get accessGet access

RESUMO

Glioblastoma (GBM) is the most aggressive primary brain tumor, providing few effective therapeutic options, given the tumor heterogeneity and the accumulation of different genetic abnormalities that cause treatment failure. The many different genetic and epigenetic alterations present in GBM lead to modification of several major signaling pathways resulting in brain tumor growth, progression, and therapeutic resistance. Many functionally important mutations have been discovered, known as neutral passengers. IDH1/2, EZH2, and DNMT3A are the best known epigenetic modifiers in cancer. These mutations are important in determining disease prognosis such that the status of the MGMT gene is a direct target of chemotherapy. For these reasons, newly developed technologies are necessary to determine new candidate targets for targeted-therapy development in GBM. The determination of mutations will aid in this and in the discovery of combinations of targeted and conventional therapies to improve GBM treatment.

Palavras-chave: mutation, IDH1, driver, GBM
CITADO POR
  1. Osborn Anne G., F. Kleine Justus, Astrozytome, in Osborn's Brain, 2019. Crossref

  2. Hensel Jonathan A., Khattar Vinayak, Ashton Reading, Ponnazhagan Selvarangan, Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity, Molecular Therapy - Oncolytics, 12, 2019. Crossref

  3. Li Yuqian, Zhu Gang, Zeng Wen, Wang Jiancai, Li Zhihong, Wang Bao, Tian Bo, Lu Dan, Zhang Xingye, Gao Guodong, Li Lihong, Long noncoding RNA AB073614 promotes the malignance of glioma by activating Wnt/β-catenin signaling through downregulating SOX7, Oncotarget, 8, 39, 2017. Crossref

  4. Rios Álvaro Fabrício Lopes, Tirapelli Daniela Pretti da Cunha, Cirino Mucio Luiz de Assis, Rodrigues Andressa Romualdo, Ramos Ester S, Carlotti Carlos Gilberto, Expression of pluripotency-related genes in human glioblastoma, Neuro-Oncology Advances, 4, 1, 2022. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain